20/20 GeneSystems is a Rockville, MD cancer diagnostics company positioned at the intersection of tumor biomarkers and cloud based, big data analytics. 20/20's first cancer test-a blood test for the early detection of lung cancer-test marketed in the Washington, D.C. area will now be commercialized on a large scale in both China and the U.S. The company's finances are supported by stable revenues and profits from an existing patented field test which has been established as a 'Gold Standard' in the biosecurity and emergency responder community.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/15/16 | $4,500,000 | Series A |
Keiretsu Forum Ping An Ventures | undisclosed |
